Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.
Gregg JR, Kim J, Logothetis C, Hanash S, Zhang X, Manyam G, Muir K; UKGPCS Collaborative Group; Giles GG, Stanford JL, Berndt SI, Kogevinas M, Brenner H, Eeles RA; PRACTICAL Consortium; Wei P, Daniel CR. Gregg JR, et al. Among authors: logothetis c. Eur Urol Oncol. 2023 Jun;6(3):282-288. doi: 10.1016/j.euo.2022.07.008. Epub 2022 Aug 20. Eur Urol Oncol. 2023. PMID: 35995710 Free PMC article.
Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort.
Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Gregg JR, et al. Among authors: logothetis c. Urology. 2020 Apr;138:91-97. doi: 10.1016/j.urology.2019.11.041. Epub 2019 Dec 30. Urology. 2020. PMID: 31899230 Free PMC article.
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.
Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Kalapara AA, et al. Eur Urol Oncol. 2020 Feb;3(1):80-91. doi: 10.1016/j.euo.2019.08.014. Epub 2019 Sep 26. Eur Urol Oncol. 2020. PMID: 31564531
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
Bruinsma SM, Nieboer D, Roobol MJ, Bangma CH, Verbeek JFM, Gnanapragasam V, Van Hemelrijck M, Frydenberg M, Lee LS, Valdagni R, Logothetis C, Steyerberg EW; the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Bruinsma SM, et al. Among authors: logothetis c. J Urol. 2021 Jul;206(1):62-68. doi: 10.1097/JU.0000000000001700. Epub 2021 Feb 22. J Urol. 2021. PMID: 33617330
Using the Movember Foundation's GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function-a retrospective study in low-risk prostate cancer patients.
Crump RT, Remmers S, Van Hemelrijck M, Helleman J, Nieboer D, Roobol MJ, Venderbos LDF; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Crump RT, et al. Transl Androl Urol. 2021 Jun;10(6):2719-2727. doi: 10.21037/tau-20-1255. Transl Androl Urol. 2021. PMID: 34295757 Free PMC article.
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Turco F, et al. Among authors: logothetis c. Eur Urol. 2022 Jul;82(1):6-11. doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17. Eur Urol. 2022. PMID: 35393158 Free PMC article.
A first step towards a global nomogram to predict disease progression for men on active surveillance.
Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, Nieboer D, Bangma C, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam V, Kattan MW; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Van Hemelrijck M, et al. Transl Androl Urol. 2021 Mar;10(3):1102-1109. doi: 10.21037/tau-20-1082. Transl Androl Urol. 2021. PMID: 33850745 Free PMC article.
5α-Reductase inhibitors for prostate-cancer prevention.
Kim J, Amos CI, Logothetis C. Kim J, et al. Among authors: logothetis c. N Engl J Med. 2011 Dec 15;365(24):2340. doi: 10.1056/NEJMc1112146. N Engl J Med. 2011. PMID: 22168662 No abstract available.
576 results